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Chronic hepatitis C infection–
induced liver fibrogenesis is 
associated with M2 macrophage 
activation
Moses T. Bility1, Kouki Nio2,3, Feng Li2,3, David R. McGivern2,3, Stanley M. Lemon2,3,4, 
Eoin R. Feeney5,6, Raymond T. Chung6,7 & Lishan Su2,3
The immuno-pathogenic mechanisms of chronic hepatitis C virus (HCV) infection remain to be 
elucidated and pose a major hurdle in treating or preventing chronic HCV-induced advanced liver 
diseases such as cirrhosis. Macrophages are a major component of the inflammatory milieu in chronic 
HCV–induced liver disease, and are generally derived from circulating inflammatory monocytes; 
however very little is known about their role in liver diseases. To investigate the activation and role 
of macrophages in chronic HCV–induced liver fibrosis, we utilized a recently developed humanized 
mouse model with autologous human immune and liver cells, human liver and blood samples and cell 
culture models of monocyte/macrophage and/or hepatic stellate cell activation. We showed that M2 
macrophage activation was associated with liver fibrosis during chronic HCV infection in the livers of 
both humanized mice and patients, and direct-acting antiviral therapy attenuated M2 macrophage 
activation and associated liver fibrosis. We demonstrated that supernatant from HCV-infected liver 
cells activated human monocytes/macrophages with M2-like phenotypes. Importantly, HCV-activated 
monocytes/macrophages promoted hepatic stellate cell activation. These results suggest a critical role 
for M2 macrophage induction in chronic HCV-associated immune dysregulation and liver fibrosis.
Chronic hepatitis C virus (HCV) infection progressively results in chronic liver inflammation, cirrhosis and 
development of hepatocellular carcinoma (HCC) over several decades1. Chronic HCV infection is also associated 
with impaired immune responses to viral antigens and chronic immune cell infiltration and activation in the 
liver, leading to progressive liver disease1. The development of direct-acting antiviral (DAA) drugs has played 
a significant role in controlling chronic HCV infection and associated liver disease; however liver fibrosis and 
HCC development and progression is still a major problem in chronically infected patients1. Delineation of the 
mechanisms by which HCV evades host immunity to establish chronic infection and promote liver disease is a 
major hurdle in treating chronic HCV-induced advanced liver disease2–4. HCV and other human hepatotropic 
pathogens including HBV have host species restriction, namely humans and chimpanzees3. To overcome host 
species restriction barrier for in vivo infection and disease modeling, we recently developed a novel humanized 
mouse model with both human immune system and liver cells, the AFC8 transgenic mouse transplanted with 
human CD34+ hematopoietic stem cells and hepatocyte progenitor cells (AFC8-hu HSC/Hep)5,6. AFC8-hu mice 
supported HCV infection in the liver and generated human T-cell response to HCV. Chronic HCV infection in 
the AFC8-hu mice induced chronic liver inflammation and cirrhosis, which correlated with activation of human 
hepatic stellate cells and expression of human fibrogenic genes5.
Chronic liver inflammation and associated liver pathology in chronic HCV infection is characterized by infil-
tration of various leukocyte populations including activated macrophages7,8. Several studies show Macrophages 
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play a critical role in modulating host response and tissue pathology, with M1 polarized macrophages promot-
ing Th1 activation and an associated anti-viral response, while M2 polarized macrophages impair Th1 acti-
vation and promote tissue fibrosis and neoplasia9–13. M1 macrophages express co-stimulatory molecules (i.e. 
membrane bound/soluble CD80, CD86), Th1 cytokines (i.e. IL12, TNFα , IL1β ), and iNOS, while M2-like mac-
rophages express scavenger molecules (i.e. membrane bound/soluble CD163, CD206), fibrogenic factors (i.e. 
TGFβ , PDGF), Th2 cytokines (i.e. IL10) and arginase 19–13. This study characterizes macrophage polarization 
in chronic HCV-induced liver inflammation and associated liver fibrosis in both humanized mice and humans. 
Additionally, this study characterizes the effect of HCV on macrophage polarization and the role of HCV acti-
vated macrophages in hepatic stellate cell activation.
Results
HCV-induced liver fibrosis is associated with human M2 macrophage activation in human-
ized-livers. Chronic liver inflammation in chronic HCV infection is characterized by infiltration of various 
leukocyte populations including activated macrophages. Several studies show macrophage polarization plays a 
critical role in modulating pathogen clearance, chronic inflammation and associated tissue pathology; with M1 
polarized macrophages promoting pathogen clearance, while M2 polarized macrophages promote Th1 impair-
ment and tissue fibrosis14. Immunohistochemical analysis of chronic HCV-associated liver inflammatory cells 
in humanized mice showed high levels of macrophages (CD68positive) of predominately M2 lineage (CD163high, 
CD206high, iNOSnegative, CD86negative) (Fig. 1A,B and Table 1). Additionally, gene expression analysis also showed 
M2 macrophage polarization (hARG1high, hCD163high, hCD80low, hCD86low) is associated with chronic HCV 
infection in humanized mice (Fig. 1C). Several studies have demonstrated that M2 macrophages secrete immuno-
suppressive cytokines, inhibitory molecules and lacks co-stimulatory molecules, thus promoting Th1 impairment 
and viral persistence in chronic viral infections14. Additionally, M2 macrophages (alternatively activated mac-
rophages) secrete pro-fibrotic cytokines and factors, thus promoting tissue fibrosis and neoplasia14. Histochemical 
analysis of chronic HCV-induced liver fibrosis in humanized mice showed that M2 macrophages localized to 
fibrotic regions (Fig. 2). Importantly, chronic HCV-induced liver fibrosis levels correlated with M2 macrophages 
levels in humanized mice (Table 1).
HCV-induced liver fibrosis is associated with M2 macrophage activation in the livers of 
humans. To confirm results from the humanized mouse model, livers from healthy controls and patients 
with chronic HCV–induced advanced liver disease (cirrhosis) were examined (Table 2). Analysis of chronic 
HCV-induced liver inflammatory cells in humans showed elevated levels of M2 macrophages (CD163high, 
iNOS negative) (Fig. 3A). Importantly, M2 macrophages in infected livers localized to fibrotic regions (Fig. 3A). 
Additionally, analysis of published gene microarray dataset of livers from healthy controls without liver disease 
and chronic HCV patients with cirrhosis and end-stage liver disease (Table 2) showed upregulation of hepatic 
stellate cell activation (α SMA, TIMP1, COL1A1 and COL1A2 mRNA levels) genes was associated with upregu-
lation of M2 macrophage genes (CD163 and CD206 mRNA levels) in chronic HCV infected livers compared to 
healthy control livers15 (Fig. 3B). Analysis of serum from healthy controls and chronic HCV infected patients with 
liver disease showed chronic inflammation in HCV infection is associated with elevated M2 macrophage activa-
tion as examined using soluble CD163 levels (M2 macrophage activation marker) (Fig. 3C); soluble CD80 levels 
(M1 macrophage activation marker) were not detectable. This result is in concordance with recently published 
studies demonstrating soluble CD163 and soluble MRC1 (M2 macrophage activation markers) levels correlate to 
the severity of chronic C hepatitis virus–induced liver fibrosis16,17.
Direct-acting antiviral (DAA) therapy is associated with reduced M2 macrophages and liver dis-
ease in chronic HCV infected patients. To further analyze the nexus between M2 macrophages and liver 
fibrogenesis in chronic HCV infection, the effect of anti-viral treatment on M2 macrophage levels was examined 
in chronic HCV patients with liver disease and undergoing treatment with direct-acting antiviral (DAA) plus 
Ribavirin (Table 2)18. Analysis of PBMCs prior to and after treatment (1.4 weeks and 24 weeks of therapy) with 
DAA (Sofosbuvir plus Ribavirin) showed virological response (prior to any virological relapse – approximately 
10% of patients relapsed) is associated with reduced monocyte/macrophage (CD68 mRNA level) and M2 mac-
rophage markers (CD163 and CD206 mRNA levels) in PBMCs (Fig. 4A)18. Also, analysis of paired chronic HCV 
infected human livers prior to and end of treatment (24 weeks of therapy) with DAA (Sofosbuvir plus Ribavirin) 
(Table 2) show virological response (prior to any virological relapse) and attenuation of liver fibrogenesis (reduced 
TIMP1 and COL1A2 mRNA levels) is associated with significantly reduced CD163 mRNA levels in the liver; 
albeit no significant differences was observed in CD68 and CD206 mRNA levels (Fig. 4B)18.
HCV induces M2 activation in monocytes and macrophages. Intracellular pathogens such as viruses 
stimulate M1 macrophage response and associated Th1 immune response in the infected host, which results 
in acute infection, virus control/clearance and host immunity; however, Th1 response is impaired in chronic 
viral infections14. Results from several studies suggest that HCV promotes immune impairment and immuno-
suppressive phenotype in monocytes/macrophages19–22. In this study we showed that culturing human THP1 
monocytic cell line and monocytes with supernatant from HCV-infected Huh7.5 cells resulted in induction of 
M2-like activation when compared to supernatant from mock-infected cells, as measured by elevated CD163, 
ARG1, IL10 and reduction of iNOS gene expression levels (Fig. 5A). Additionally, culturing M1 (GM-CSF) or M2 
(MCSF)-polarized macrophages with supernatant from HCV-infected Huh7.5 cells resulted in induction of M2 
macrophage activation when compared to supernatant from mock-infected cells, as measured by elevated ARG1 
gene expression and IL10 cytokine level, and reduction of M1 macrophage activation as measured by reduced 
IL12 cytokine level (Fig. 5B,C).
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HCV-activated monocytes/macrophages promote hepatic stellate cell activation. As men-
tioned earlier, several studies have suggested that macrophage polarization plays a critical role in tissue remod-
eling and pathology; with M2 macrophage directly promote tissue fibrosis via the production of pro-fibrogenic 
factors and molecules. Hepatic stellate cell activation is a highly regulated biological process with critical roles 
for parenchymal cells (hepatocytes), non-parenchymal cells (i.e. monocytes and macrophages), and the stroma23. 
Here, we examined the effect of HCV activated monocytes/macrophages on hepatic stellate cell activation using 
human hepatic stellate cell line (LX2 cell line), and different stroma conditions to mimic physiological condi-
tions. Co-culturing human hepatic stellate cells (LX2) with HCV-activated monocytic cells (THP1) in plastic 
stroma conditions resulted in upregulation of well-established hepatic stellate cell activation markers compared 
to mock control, as examined using gene expression analysis (α SMA and COL1A1) (Fig. 6A). Supernatant from 
HCV-infected Huh7.5 cells had negligible effect on LX2 cell activation when compared to supernatant from 
mock-infected cells (Fig. 6A). Here we also confirmed the critical role of the stroma in modulating hepatic stel-
late cell activation state; culturing hepatic stellate cells (LX2 cell line) on Matrigel coated plates induced cellular 
Figure 1. Human infiltrating macrophages express M2 macrophage markers in HCV-infected humanized 
mice livers. Representative livers of NTP-HCV (Non-transplanted mice inoculated with HCV), Hep/HSC TP - 
Mock or HCV (humanized mice with human hepatocytes and immune cells inoculated with Mock or HCV+ 
serum), Hep TP-HCV (humanized mice transplanted with adult hepatocytes inoculated with HCV) were 
stained for human pan-macrophage marker - hCD68 (A) and human M2 (hCD206, hCD163) and M1 (hiNOS, 
hCD86) markers (B). Additionally, liver RNA was isolated from Hep/HSC TP – Mock (N = 3) or HCV (N = 10) 
and qPCR analysis was performed to examine human (C) M1 macrophage polarization markers (hCD80, 
hCD86) and (D) M2 macrophage polarization markers (hARG1, hCD163).
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quiescence when compared to plastic plates as examined using morphological analysis (Fig. 6B), and gene expres-
sion analysis (Data not shown). HCV (JFH1-Huh7.5 supernatant) inoculation of human monocytes (THP1 cell 
line) and LX2 cells co-cultured in Matrigel coated plates resulted in hepatic stellate cell activation when compared 
to mock control as examined using morphological analysis, with quiescent LX2 cells exhibiting the characteristic 
round clump appearance, while activated LX2 cells exhibiting the well-established characteristic star-like mor-
phology (Fig. 6B). We confirmed those results in co-cultures of primary human monocytes/macrophages and 
hepatic stellate cells. To examine the effect of HCV-activated primary monocytes on hepatic stellate cells activa-
tion, HCV (genotype 2 – JFH1)-activated primary monocytes were co-cultured with LX2 cells on plastic plates. 
Co-culturing HCV-activated primary monocytes with LX2 cells resulted in upregulation of hepatic stellate cell 
activation markers compared to mock control, as examined using gene expression analysis (α SMA and COL1A1) 
(Fig. 6C); HCV supernatant had negligible effect on the expression of hepatic stellate cell activation markers when 
compared to mock supernatant (Fig. 6C). Additionally, co-culture of quiescent LX2 cells and primary monocytes 
in Matrigel coated plates with HCV (genotype 1 – H77S.3) supernatant also resulted in upregulation of hepatic 
stellate cell activation markers when compared to mock control as examined using gene expression analysis 
(α SMA) (Fig. 6D).
Discussion
Chronic hepatitis C virus (HCV) infection affects approximately 2–3% of the global population and cause severe 
morbidity and mortality, due to progressive liver inflammation, cirrhosis and hepatocellular carcinoma (HCC)1. 
The recent introduction of novel direct-acting anti-viral (DAA) therapies have demonstrated robust clearance 
of chronic HCV infection across several genotypes, however DAA treatment does not directly target cirrhosis 
and HCC1. Additionally, several challenges in HCV therapies remains, including drug resistant HCV strains, 
advanced liver disease (cirrhosis and HCC), and the cost of care1. Therefore, elucidating the mechanisms by 
which chronic HCV infection induces liver disease is a major hurdle in treating HCV-induced advanced liver 
disease such as cirrhosis3. Chronic liver inflammation is a hallmark of chronic HCV infection and is characterized 
by infiltration of a myriad of immune cells including macrophages7,8. Macrophages are innate immune cells with 
critical roles in host defense, immune response, tissue maintenance and tissue repair14. Macrophages are broadly 
delineated into two categories, namely M1 macrophages and M2 macrophages14. Importantly, several reports 
suggest macrophage polarization plays a critical role in modulating pathogen clearance, chronic inflammation 
and associated tissue pathology; with M1 polarized macrophages promoting anti-viral Th1 immune response 
and viral clearance, while M2 polarized macrophages impair Th1 immune response and promote tissue inflam-
mation and fibrosis14. M2 macrophages play critical roles in wound repair, secreting anti-inflammatory cytokines 
and redistributing micronutrients during repair following injury; however, during chronic infection, M2 mac-
rophages promote tissue fibrosis, cancer development and impair Th1 response, thus promoting pathogen persis-
tence and associated tissue pathology14.
In order to understand the mechanism by which chronic HCV induces liver disease, we examined the rela-
tionship between macrophage polarization and liver disease, specifically cirrhosis. In this report we demonstrated 
that liver inflammation and cirrhosis in chronic HCV infected humanized mice livers is associated with M2 
macrophages. HCV-induced M2 macrophages localized to fibrotic regions in HCV-infected livers in humanized 
mice. Importantly, results from chronic HCV infected patients confirmed that chronic HCV infection in the liver 
ID Model Inoculum
Time Post 
Inoculation Liver Viral Loada
Liver 
Diseaseb
Liver 
M2 MØ
1 Non-hu-mice Mock (PBS) 11.4 Weeks ND F0 —
117 HSC-Hep hu-mice Mock (Human Sera) 6.8 Weeks ND F0 —
88*4 HSC-Hep hu-mice Mock (Human Sera) 13.8 Weeks ND F0 —
99*4 HSC-Hep hu-mice Mock (Human Sera) 13.8 Weeks ND F0 —
4 Non-hu-mice HCV GT1 #1 (9E5 copies/mL) 15.7 Weeks ND F0 —
110 Adult Hep hu-mice HCV GT1 #1 (9E5 copies/mL) 15.7 Weeks 0.18E5 copies/ug RNA F0 —
108 HSC-Hep hu-mice HCV GT1 #1 (9E5 copies/mL) 4.6 Weeks 1.64E5 copies/ug RNA F3 + + + 
109 HSC-Hep hu-mice HCV GT1 #1 (9E5 copies/mL) 11.4 Weeks 0.14E5 copies/ug RNA F3 + + + 
90*4 HSC-Hep hu-mice HCV GT1 #2 (5E5 copies/mL) 4.8 Weeks 3.23E5 copies/ug RNA F3 + + + 
91*4 HSC-Hep hu-mice HCV GT1 #2 (5E5 copies/mL) 8.1 Weeks 1.68E5 copies/ug RNA F2 + + 
92*4 HSC-Hep hu-mice HCV GT1 #2 (5E5 copies/mL) 13.8 Weeks ND F4 + + + 
Table 1.  HCV–induced liver inflammation and fibrosis is associated with M2 macrophage activation in the 
liver in the AFC8 humanized mouse model. Notes: ID = Identification; HSC-Hep hu-mice = AFC8-hu HSC/
Hep mouse; Adult Hep hu-mice = AFC8-hu Adult hepatocytes mouse; Non-hu mice = Non transplanted AFC8 
mouse; Inoculum= Mock (PBS or Sera from healthy control humans), HCV#1 (HCV positive serum from 
patient #1), HCV#2 (HCV positive serum from patient #2), aChronic HCV = Persistent HCV infection markers 
(HCV RNA) detected in animal as reported in Washburn et al.5; bLiver disease = METAVIR score (Liver 
fibrosis stage and necroinflammatory activity) as reported in Washburn et al. no liver disease (F0), mild liver 
fibrosis (1), moderate liver fibrosis (2), severe liver fibrosis (> 3); Liver M2 MØ = Relative M2-like (hCD163+ ) 
macrophage levels, no M2 macrophages (− ), low M2 macrophage level (+ ), intermediate M2 macrophage level 
(+ + ), high M2 macrophage level (+ + + ).
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is associated with M2 macrophage accumulation. Additionally, we demonstrated that chronic HCV infection 
and associated liver disease is also associated with levels of M2 macrophage activation marker in the serum. We 
also demonstrated that DAA treatment-induced virological response and liver fibrogenesis attenuation is asso-
ciated with attenuation of M2 macrophages both in the blood and the liver. We demonstrated that supernatant 
from HCV infected hepatocytes promotes M2 macrophage polarization in human monocytic cells. Additionally, 
supernatant from HCV infected hepatocytes promotes M2 macrophage polarization in both human M1 and M2 
polarized macrophages. Importantly, we provide evidence that suggests HCV-activated monocytes/macrophages 
promote hepatic stellate cell activation in tissue culture models.
There are several limitations in this study that will be address in future studies. Future in vivo mechanistic 
studies will examine the role of M2 macrophages in promoting and maintaining liver fibrosis in HCV infec-
tion via targeting M2 macrophages using small molecules and macrophage depleting agents. Additionally, future 
studies will address the mechanism by which HCV promotes M2 macrophage activation, and the mechanism by 
which HCV-activated monocytes/macrophages promote hepatic stellate cell activation. Results from this study 
suggest that the hepatitis C virus could mediate M2 macrophage activation in human monocytes/macrophages. 
Several studies have demonstrated a critical role for macrophages in liver fibrosis, with soluble factors such as 
TGF-B, PDGF, VEGF as potent mediators of macrophage pro-fibrotic activity. Future studies will investigate the 
expression of pro-fibrotic factors such as TGF-B, PDGF, VEGF in HCV-activated macrophages and their role of 
hepatic stellate cell activation. A limitation of this study is that we did not extensively characterized HCV-induced 
M2 macrophages, and the possibility that those cells could acquire myofibroblast-like characteristics and deposit 
collagen, which are properties of mesenchymal-lineage cells (i.e. activated hepatic stellate cells). Future stud-
ies will address the possibility of monocyte/macrophage to mesenchymal transition in HCV-induced M2 mac-
rophages, and the ability of those cells to express well-established markers of hepatic stellate cell activation and 
promote fibrogenesis. Future studies will also address the relationship between HCV viral load and monocyte/
macrophage activation, and the effect of viral clearance on macrophage activation in the liver and the effect on 
advance liver disease such as cirrhosis and hepatocellular carcinoma. The relationship between M2 monocyte/
macrophage activation in the blood and liver is also a topic of significant interest, and could provide insight unto 
the mechanism of M2 macrophage-associated liver inflammation and the mechanism of liver disease; future stud-
ies will address the mechanism of monocyte/macrophage trafficking in the inflamed-livers in humanized mice.
Figure 2. Human infiltrating macrophages localize to fibrotic regions in livers of HCV-infected humanized 
mice. (A) Representative serial liver sections of NTP (Non-transplanted mice inoculated with HCV); Hep/
HSC TP - Mock or HCV (humanized mice with human hepatocytes and immune cells inoculated with Mock or 
HCV+ serum); Hep TP (mice transplanted with human adult hepatocytes inoculated with HCV) were stained 
for M1 (hiNOS/Red) and M2 (hCD163/Brown) macrophage polarization markers and collagen (Sirius Red/Fast 
Green). Black arrows denote same regions on serial slides.
GEO 
NCBI ID
Clinical Trial 
Identifier
Infection 
Status Age Liver disease Score Treatment Outcome
GSE14323 LTCDSa Uninfected Adult Normal NA NA
GSE14323 NCT00096733 HCVb 50.1 (10.9)c 14.9 (5.7) MELD NA End-stage liver disease
GSE51699 NCT01441180 HCVgt1 54 (50, 57)d 0-1 (80%)3-4 (20%) Knodell-HAI
SOF+ RBV 
(24Weeks) SVR (90%) Relapsed (10%)
Table 2.  HCV–induced liver inflammation and fibrosis is associated with M2 macrophage activation in 
the liver humans. Notes: ID = Identification; Liver Tissue Cell Distribution System (LTCDS; a = Not Clinical 
Trial); b = Includes all HCV genotypes; c = Mean (Standard Deviation) (Olthoff, K.M et al.30), d = Median 
(Interquartile range) (Osinusi, A. et al.31); Model For End-Stage Liver Disease (MELD) and standard deviation 
(#); Knodell Histology Activity Index (Knodell-HAI) and percentage with score range (%); NA = Non-
applicable; SVR = sustained virologic response.
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Our results are consistent with recently published studies showing chronic liver infections (chronic hepatitis 
B; chronic Opisthorchis viverrini infection) and associated hepatobiliary fibrosis and cancer is associated with M2 
macrophages24,25. Chronic HBV infection-induced liver fibrosis in both humans and humanized mice is associ-
ated with M2 macrophages, which are localized to fibrotic regions24. Importantly, acute HBV-induced accelerated 
liver fibrosis and failure is also associated with upregulation of M2 macrophage genes, and downregulation of M1 
macrophage genes24 using published gene microarray dataset26,27. Additionally, chronic Opisthorchis viverrini 
(OV) infection-induced liver fibrosis in both humans and Syrian golden hamsters was associated with M2 mac-
rophages, which localized to fibrotic regions and neoplastic regions25. Those results and this study suggest a pos-
sible underlying mechanism by which liver pathogens (i.e. HCV, HBV, and OV) and other non-infectious agents 
(i.e. high fat diet), along with co-morbidities (i.e. HIV co-infection) modulate host macrophage polarization to 
promote hepatobiliary fibrogenesis and carcinogenesis.
In summary, this study sheds light on the role of M2-like macrophages in modulating liver fibrosis in chronic 
HCV infection. Importantly, we showed that HCV infection-induced M2 macrophage activation in the liver 
may be critical for the induction of hepatic fibrogenesis (Fig. 6). Results from this study suggest a critical role for 
“M2-like” macrophages in chronic HCV-induced immune impairment, immune dysregulation and liver pathol-
ogy; suggesting a novel cellular target for HCV therapeutics development. Results from this study also demon-
strate that the humanized mouse model and cell culture models will provide a novel mechanistic and pre-clinical 
platform for evaluating therapeutics targeting human macrophages in chronic HCV infection and its associated 
liver diseases.
Methods
Ethics statement. All animal experiments were conducted following NIH guidelines for housing and care 
of laboratory animals and in accordance with protocols approved by the institution’s Institutional Animal Care 
and Use Committee (protocol number 10–107) at the University of North Carolina at Chapel Hill. Liver gene 
expression profile analyses in patients were obtained from a dataset in Gene Expression Omnibus (GEO)/NCBI 
database; the reports followed NIH research ethics guidelines. Harvard/MGH Research and Ethics Committee 
Figure 3. HCV-induced liver fibrosis in humans is associated with infiltrating macrophages expressing M2 
macrophage activation markers. (A) Representative serial liver sections of healthy controls or chronic HCV 
infected patients were stained for M1 (hiNOS/Red) and M2 (hCD163/Brown) macrophage and collagen (Sirius 
Red/Fast Green). (B) Chronic HCV-induced liver fibrosis (α SMA, TIMP1, COL1A1, COL1A2) is associated 
with upregulation of M2 macrophage markers (CD163, CD206) in livers of chronic HCV patients (N = 41) 
compared to livers of healthy controls (N = 19). (C) Elevated serum levels of soluble M2 macrophage activation 
marker (Soluble CD163) in chronic HCV patients with liver fibrosis (N = 10) compared to healthy controls 
(N = 10).
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and the independent ethics committee approved human study protocols; written informed consent was obtained 
from all participants.
Analysis of HCV-induced liver fibrosis and macrophage polarization in humanized mice and 
humans. AFC8 liver and immune system - humanized mice or non-humanized control mice were inoculated 
iv with clinical isolates of HCV5. At termination, humanized liver tissues were immediately fixed in formalin 
or frozen. Additionally, liver tissue samples were collected from healthy controls (HCV seronegative individ-
uals with normal liver function) and HCV seropositive patients with liver fibrosis and abnormal liver function 
and fixed in formalin; serum samples were also collected from those patients and stored at − 80 degree Celsius. 
All animal and human protocols were approved and followed institutional and national guidelines. Fixed tis-
sues were paraffin embedded and sections were stained with Sirius red/fast green (liver fibrosis) or with indi-
cated antibodies. Immunoreactivity was determined by incubation with DAB substrate (Pierce) or Vulcan red 
(Dako), and counterstained with hematoxylin28,29. Gene expression was examined using qPCR and Sybr Green 
kit, following manufacturer’s recommended procedures (Invitrogen). Microarray gene expression analysis was 
performed on publicly available microarray dataset from healthy controls without liver disease and chronic HCV 
patients with cirrhosis15,30 (GEO accession: GSE14323), and from chronic HCV patients undergoing direct-acting 
antiviral therapy18,31 (GEO accession: GSE51699) using GEOR (NCBI Software). For GSE14323 microarray 
studies, livers from adult HCV RNA positive patients with advanced liver fibrosis and undergoing liver trans-
plantation due to end-stage liver disease were obtained via the Adult Living Donor Liver Transplant Cohort 
Study (NCT00096733) (Table 2); livers from adult HCV RNA negative liver transplant donors with normal 
Figure 4. Direct-acting antiviral (DAA) therapy is associated with reduced M2 macrophage activation 
genes and liver disease in chronic HCV-infected patients. (A) Direct-acting antiviral (DAA) therapy in 
chronic HCV patients is associated with reduced macrophage (CD68) and M2 macrophage markers (CD163, 
CD206) in peripheral blood mononuclear cells (PBMCs) after 1.4 weeks (N = 8) and 24 weeks of therapy 
(N = 12), when compared to pre-treatment (N = 4). (B) DAA therapy results in attenuation of liver fibrogenesis 
(COL1A2, TIMP1), associated with significantly reduced CD163 mRNA levels in the liver, as examined in 
paired chronic HCV patients biopsies prior to (N = 8) and after (N = 8) treatment regimen (24 weeks of DAA 
therapy).
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liver function and histopathology were obtained through the Liver Tissue Cell Distribution System (Table 2)15. 
For GSE51699 microarray studies, blood and liver samples from adult HCV genotype-1 RNA positive patients, 
some with advanced liver fibrosis (20%) as measured using Knodell-HAI scores by the study investigators were 
obtained as part of a clinical trial for direct-acting antiviral (DAA) (NCT01441180) (Table 2). DAA reduced viral 
load in all patients, as documented by reduction below lower limit of detection (LLOD) of 3 IU/ml. Samples were 
collected prior to viral relapse, which occurred in a minority of patients (10%)18. Soluble CD163 and soluble 
CD80 were examined in serum samples of adult healthy controls (HCV RNA negative individuals with normal 
liver function) and HCV RNA positive patients with liver fibrosis and abnormal liver function using ELISA and 
following manufacturers recommended procedures (R&D systems).
Cell culture models for monocyte/macrophage and hepatic stellate cell activation. Human 
PBMCs were isolated from buffy coats of healthy HIV/HBV/HCV sero/qPCR negative blood donors by 
Ficoll-paque density gradient centrifugation. Cells were then washed, suspended in RPMI containing pen/strep 
(1%), glutamine (1%), heat-inactivated FBS (10%), and seeded on tissue culture plates. To isolate primary mono-
cytes, non-adherent cells were removed by gentle pipette aspiration after 1.5 h of incubation at 37 °C in a humid-
ified atmosphere containing 5% CO2. Equal volume of fresh complete medium was then added to each flask and 
attached cells (primary monocytes) at approximately 70–80% confluency were cultured for 6 additional days at 
37 °C in 5% CO2 in presence of either rHuGM-CSF (100 ng/ml) (M1 macrophages) or rHuM-CSF (100 ng/ml) 
(M2 macrophages) for differentiation into polarized M1 or M2 - monocyte derived macrophages. THP1 
Figure 5. HCV induces M2 activation in monocytes and macrophages. (A) Human monocytic cells (THP1) 
were inoculated with supernatant from JFH1/genotype 2-infected Huh7.5 cells or mock-infected Huh7.5 cells 
and macrophage polarization was examined using gene expression analysis after 6 days. (B,C) Primary human 
monocytes were differentiated to M1 or M2 macrophages and were inoculated with supernatant from JFH1/
genotype 2-infected Huh7.5 cells or mock-infected Huh7.5 cells and macrophage polarization markers were 
examined using gene expression (B) and cytokine (C) analysis after 6 days.
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monocytes and monocyte-derived primary M1 or M2 macrophages were washed and treated with supernatant 
containing HCV (supernatant from JFH1/genotype 2-infected Huh7.5 cells at 0.5 virus particles per monocytes/
macrophages) or Mock (supernatant from mock-infected Huh7.5 cells) for 6 days. M1 and M2 macrophage acti-
vation were examined using cytokine analysis (BD Biosciences) and qPCR (Invitrogen) following manufactures’ 
recommended procedures. For co-culture experiments examining the effect of HCV-activated monocytes on 
hepatic stellate cell activation, human monocytic cells (THP1) or primary monocytes were cultured with super-
natant containing HCV (supernatant from H77S.3/genotype 1 or JFH1/genotype 2-infected Huh7.5 cells at 0.5 
virus particles per monocytes/macrophages) or Mock (supernatant from mock-infected Huh7.5 cells) for 6 days; 
subsequently, HCV or mock-stimulated monocytes were co-culture with human hepatic stellate cells (LX2) at 
equal proportion on plastic surface for an additional 24 hours and hepatic stellate cell activation was examined 
using qPCR (Life Technologies). Additionally, human monocytic cells (THP1) were inoculated with supernatant 
Figure 6. Human macrophages exposed to HCV promote hepatic stellate cell activation. (A) Human 
monocytic cells (THP1) were cultured with supernatant from H77S.3/genotype 1 or JFH1/genotype 
2-infected Huh7.5 cells or mock-infected Huh7.5 cells for 6 days, and subsequently co-cultured with human 
hepatic stellate cells (LX2) on plastic plates for 24 hours; fibrotic gene expression was examined by qPCR. 
(B) Human hepatic stellate cells (LX2 cells) cultured on Matrigel coated plates to induce cellular quiescence, 
were subsequently co-cultured with human monocytic cell line (THP1 cells) and supernatant from JFH1/
genotype 2-infected Huh7.5 cells or from mock-infected Huh7.5 cells, and hepatic stellate cells activation was 
examined morphologically after 3 days (black arrows: quiescent cells phenotype - round clumps; while activated 
phenotype - fibroblast-like shape). (C) Primary human monocytes were cultured with supernatant from JFH1/
genotype 2-infected Huh7.5 cells or mock-infected Huh7.5 cells for 6 days, and subsequently co-cultured with 
human hepatic stellate cells (LX2) on plastic plates for 24 hours; fibrotic gene expression was examined by 
qPCR. (D) Human hepatic stellate cell line (LX2), cultured on Matrigel coated plates to induce quiescence, were 
subsequently co-cultured with primary monocytes and supernatant from H77S.3/genotype 1-infected Huh7.5 
cells or mock-infected Huh7.5 cells and hepatic stellate cell activation markers was analyzed after 3 days by gene 
expression.
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containing HCV (supernatant from JFH1/genotype 2-infected Huh7.5 cells at 0.5 virus particles per monocytes/
macrophages) or Mock (supernatant from mock-infected Huh7.5 cells) and co-cultured with human hepatic 
stellate cells at equal proportion on Matrigel (BD Biosciences) and hepatic stellate cell activation were examined 
using qPCR (Life Technologies) after 3 days.
Statistical analysis. We used unpaired or paired two-tailed Student’s t-tests or ANOVA for comparisons. 
p < 0.05 is considered significant. All data are reported as means ± standard error.
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